Kala Pharmaceuticals Inc., a developer of ophthalmic products based on muscle-penetrating particle technology, has raised $68 million in Series C funding. Longitude Capital led the round, and was joined by OrbiMed Advisors, Vivo Capital, CAM Capital, RA Capital Management, Wellington Management, Polaris Partners, Lux Capital and CVF LLC.

Kala Pharmaceuticals, Inc. is a leading developer of improved treatments for diseases that affect mucosal tissues. Using its proprietary mucus penetrating particle (MPP) technology platform, Kala is able to formulate active pharmaceutical ingredients so they are able to pass through human mucus secretions, in diverse organs, including the respiratory tract, eye, cervicovaginal tract and gastrointestinal tract. Kala's formulations result in a rapid, uniform distribution of drug-loaded particles in human mucus leading to enhanced local efficacy and reduced systemic exposure. The company is advancing its own internal pipeline while establishing research and development collaborations with select partners.